A Phase II trial is being conducted to investigate the potential of psilocybin-assisted psychotherapy as a treatment for binge eating disorder (BED).
Cybin has partnered with Clinilabs to carry out its Phase 1/2a clinical trial of CYB003, a proprietary deuterated psilocybin analogue.
Results from two-combined studies have revealed that psilocybin-assisted therapy increased brain activity in people with depression for up to three weeks following use.
Cybin Inc.
Leading UK psychedelics company Compass Pathways is entering into a pioneering collaboration with King’s College London and South London and Maudsley NHS Foundation Trust to accelerate...
Data from Wesana Health indicates that administration of imipramine given three weeks following a psilocybin loading dose provided a 39 per cent improvement in depressive behaviours...
Results from a systematic review have led to the conclusion that psilocybin is safe to administer in clinical settings, and that there is a need to...
The licence will enable research that will give a deeper understanding of psychedelic mushrooms and their interaction with the human body.
Backed by three top psychiatrists, 161 cluster headache sufferers in the UK have written an open letter to Home Office ministers Savid Javid and Kit Malthouse...
Findings from a study comparing the acute effects of the two compounds suggest that 20 mg psilocybin is equivalent to 100 μg LSD, and 30 mg...